This insider cluster is routine post-earnings option exercise and sell-to-cover activity by two EVPs. At 0.0004% of market cap, it carries no material signal. Monitor for any C-suite open-market sales or purchases in the coming weeks, but this filing alone does not warrant a trading action.
MRK drugs
MRK drug pipeline →- ● ENFLONSIA 4/10 Approved · PDUFA date Mar 22, 2027
- ● IDVYNSO 4/10 Approved · PDUFA date Apr 22, 2027
- ▲ sac-TMT 6/10 Filed/PDUFA (Phase 3 data complete; BLA under priority review) · PDUFA date Jun 15, 2027
- ● GARDASIL 4/10 Approved
- ● LAGEVRIO 4/10 EUA (Emergency Use Authorization) / Marketed
- 15 more · All MRK drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 10 $130.92entry
- T+1 · 3mo ago −0.38%α −0.06% · $130.42
- T+5 · 3mo ago +3.86%α +3.90% · $135.97
- T+20 · 2mo ago +13.40%α +14.31% · $148.46
- T+60 · 14d ago +10.50%α +12.92% · $144.67
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two EVPs at Merck (Williams and Maraldo) executed open-market sales totaling ~$1.4M on August 5, 2026, one day after the company reported Q2 earnings that beat consensus on revenue and EPS. The sales are part of a larger cluster of option exercises and same-day share disposals, consistent with routine post-vesting tax and liquidity management. At $317B market cap, the $1.4M represents ~0.0004% of market cap, trivial and non-informative.
Key Financial Metrics
Key Facts
- Two EVPs sold a combined ~$1.4M in open-market transactions on Aug 5, 2026
- Sales occurred one day after Merck's Q2 2026 earnings beat (revenue $16.6B, +5% YoY, consensus $16.37B)
- Total open-market sales represent ~0.0004% of Merck's $317B market cap, immaterial
- Both sales were part of larger option exercise-and-sell patterns, consistent with routine post-vesting tax withholding and diversification
- No C-suite (CEO/CFO) participation; no open-market purchases in the cluster
Financial Impact
Open-market sales of ~$1.4M, representing ~0.0004% of market cap, trivial
Risk Factors
- Insider sales may continue as other executives exercise options post-earnings
- No bearish signal from this cluster, risk of over-interpreting routine activity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-MRK-1786169751573 |
Track record
34 reports on MRK
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +16.92% at T+20 after the Aug 6, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $147.76 Now $147.76 −0.00% settles Feb 11
- Nov 9, 20268d ago PTAB Trial Neutral 2/10 Entry $148.05 Now $147.76 −0.20% settles Feb 8
- Nov 3, 202613d ago 3 Neutral 2/10 Entry $144.67 Now $147.76 +2.14% settles Feb 1
- Nov 3, 202613d ago Institutional Cluster Bearish 4/10 Entry $144.67 Now $147.76 −2.14% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $144.67 Now $147.76 +2.14% settles Feb 1
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $146.33 Now $147.76 +0.98% settles Jan 27
- Oct 22, 202625d ago 3/A Neutral 1/10 Entry $145.27 Now $147.76 +1.71% settles Jan 21
- Oct 21, 202627d ago PTAB Trial Neutral 3/10 Entry $147.24 Now $147.76 +0.35% settles Jan 20
- Oct 15, 20264w ago PTAB Trial Bullish 6/10 Entry $145.95 Now $147.76 +1.24% settles Jan 13
- Oct 15, 20264w ago PTAB Trial Bullish 5/10 Entry $145.95 Now $147.76 +1.24% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers